Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
María José CasanovaÓscar NantesPilar VarelaMilagros Vela-GonzálezMontserrat RiveroOlivia Sierra-GabardaSabino RiestraManuel Barreiro-de AcostaMaría Del Mar Martín-RodríguezCarla Jerusalén Gargallo-PuyueloCristina ReygosaRoser MuñozIrene García de la Filia-MolinaAndrea Núñez-OrtizLilyan KolleMargalida CalafatJose Maria HuguetEva Iglesias-FloresTeresa de Jesús Martínez-PérezOrencio BoschJosé María Duque-AlcortaSantiago Frago-LarramonaManuel Van DomselaarVíctor Manuel González-CosanoLuis BujandaSaioa RubioAlejo ManceboBeatriz CastroSantiago García-LópezRuth de FranciscoLaura Nieto-GarcíaViviana LaredoAna Gutiérrez-CasbasFrancisco MesoneroEduardo Leo-CarnereroFiorella CañeteLucía RuizBeatriz GrosMaría Del Moral-MartínezCristina RodríguezMaria ChaparroFrancisco Javier García-AlonsoPublished in: Alimentary pharmacology & therapeutics (2023)
Switching to ADA biosimilar did not impair patients' outcomes in comparison with maintaining on the originator.